Brian M. Culley - 11 Feb 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Signature
/s/ Brian M. Culley
Issuer symbol
LCTX
Transactions as of
11 Feb 2025
Net transactions value
-$8,156
Form type
4
Filing time
12 Feb 2025, 16:30:06 UTC
Previous filing
22 Nov 2024
Next filing
12 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares Options Exercise +31,249 +16% 226,091 11 Feb 2025 Direct F1, F2
transaction LCTX Common Shares Tax liability $8,156 -12,547 -5.5% $0.6500 213,544 11 Feb 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Options Exercise $0 -31,249 -50% $0.000000 31,250 11 Feb 2025 Common Shares 31,249 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
F4 The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.